Plaque psoriasis and other autoimmune diseases
AbbVie Rövid összefoglaló Psoriasis is a common, chronic, inflammatory disorder which primarily affects the skin and joints and is associated with impairment of quality of life. The main objective of this study is to assess how safe risankizumab is compared to other therapies in treating adult participants with psoriasis in real world setting in the United States.
Adverse events will be assessed using secondary sources. Skyrizi Risankizumab is an approved drug for the treatment of moderate to severe psoriasis in the United States. Participants who are prescribed risankizumab or other comparator drugs in the real world setting will be included in this study.
Data from approximately risankizumab new users and other comparator new users across the United States will be evaluated. Participants will receive subcutaneous risankizumab injection or other comparative drugs as prescribed by their physician.
Data from these participants will be collected for approximately 10 years.
There will be no additional burden for participants in this study compared to their standard of care as secondary data sources will be used.